NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 184 filers reported holding NEKTAR THERAPEUTICS in Q2 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $7,033 | -72.6% | 10,005 | -11.8% | 0.00% | -100.0% |
Q4 2022 | $25,628 | +1.5% | 11,340 | +43.7% | 0.00% | 0.0% |
Q3 2022 | $25,248 | -39.8% | 7,890 | -28.5% | 0.00% | -50.0% |
Q2 2022 | $41,918 | -13.4% | 11,031 | +208.0% | 0.00% | +100.0% |
Q4 2021 | $48,393 | -91.9% | 3,582 | -89.3% | 0.00% | -88.9% |
Q3 2021 | $600,439 | +1.9% | 33,432 | -2.7% | 0.01% | +12.5% |
Q2 2021 | $589,412 | -14.0% | 34,348 | +0.2% | 0.01% | -20.0% |
Q1 2021 | $685,440 | +25.8% | 34,272 | +6.9% | 0.01% | +25.0% |
Q4 2020 | $544,850 | +0.1% | 32,050 | -2.4% | 0.01% | -20.0% |
Q3 2020 | $544,567 | -31.7% | 32,825 | -4.6% | 0.01% | -28.6% |
Q2 2020 | $796,959 | -6.7% | 34,411 | -28.1% | 0.01% | -22.2% |
Q1 2020 | $853,766 | -21.6% | 47,830 | -5.2% | 0.02% | 0.0% |
Q4 2019 | $1,088,488 | +116.2% | 50,428 | +82.4% | 0.02% | +100.0% |
Q3 2019 | $503,481 | -57.9% | 27,641 | -17.8% | 0.01% | -55.0% |
Q2 2019 | $1,195,773 | +10.6% | 33,608 | +4.4% | 0.02% | 0.0% |
Q1 2019 | $1,081,651 | -0.0% | 32,192 | -2.2% | 0.02% | -9.1% |
Q4 2018 | $1,081,752 | -45.4% | 32,910 | +1.2% | 0.02% | -37.1% |
Q3 2018 | $1,981,749 | -99.9% | 32,509 | +2.0% | 0.04% | +40.0% |
Q2 2018 | $1,556,946,000 | -78.1% | 31,885 | -52.3% | 0.02% | -75.0% |
Q1 2018 | $7,106,776,000 | +258798.9% | 66,881 | +45.5% | 0.10% | +177.8% |
Q4 2017 | $2,745,000 | +14.9% | 45,958 | -53.8% | 0.04% | +140.0% |
Q3 2017 | $2,390,000 | +22.8% | 99,566 | 0.0% | 0.02% | +15.4% |
Q2 2017 | $1,947,000 | -16.2% | 99,566 | +0.6% | 0.01% | -18.8% |
Q1 2017 | $2,323,000 | +87.2% | 98,982 | -2.1% | 0.02% | +77.8% |
Q4 2016 | $1,241,000 | -21.7% | 101,124 | +9.7% | 0.01% | -25.0% |
Q3 2016 | $1,584,000 | +19.7% | 92,189 | -0.9% | 0.01% | +20.0% |
Q2 2016 | $1,323,000 | +3.5% | 92,980 | 0.0% | 0.01% | 0.0% |
Q1 2016 | $1,278,000 | -17.7% | 92,980 | +0.9% | 0.01% | -16.7% |
Q4 2015 | $1,553,000 | +53.8% | 92,158 | 0.0% | 0.01% | +71.4% |
Q3 2015 | $1,010,000 | -13.4% | 92,158 | -1.1% | 0.01% | -12.5% |
Q2 2015 | $1,166,000 | +9.0% | 93,217 | -4.2% | 0.01% | 0.0% |
Q1 2015 | $1,070,000 | -30.2% | 97,294 | -1.6% | 0.01% | -27.3% |
Q4 2014 | $1,532,000 | +29.6% | 98,838 | +0.9% | 0.01% | +22.2% |
Q3 2014 | $1,182,000 | -5.8% | 97,927 | 0.0% | 0.01% | 0.0% |
Q2 2014 | $1,255,000 | +6.4% | 97,927 | +0.6% | 0.01% | +12.5% |
Q1 2014 | $1,180,000 | +7.6% | 97,349 | +0.7% | 0.01% | 0.0% |
Q4 2013 | $1,097,000 | +8.6% | 96,658 | 0.0% | 0.01% | 0.0% |
Q3 2013 | $1,010,000 | -9.5% | 96,658 | 0.0% | 0.01% | -11.1% |
Q2 2013 | $1,116,000 | – | 96,658 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |